Stocks · News reference

Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss

Jul 17, 2026, 11:32 AMBenzinga Newsdesk

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MANE

Source: benzinga
Observed: Jul 17, 2026, 11:32 AM
Checked: Jul 17, 2026, 11:32 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 11, 2026, 8:54 PMBenzinga Newsdesk
Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate
Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 10.77 percent. This is a 97.6 percent increase over losses of $(24.19) per share from the
Read original at benzinga
MANE
SEC EDGARAug 11, 2026, 12:15 PMSEC EDGAR
8-K filing — Veradermics, Inc (MANE)
Filed: 2026-08-11 AccNo: 0001827635-26-000028 Size: 641 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
MANE
BenzingaJul 17, 2026, 5:52 PMBenzinga Newsdesk
Veradermics shares are trading higher after the company announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss.
Read original at benzinga
MANE

Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss

Connected markets

Related headlines

Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate

8-K filing — Veradermics, Inc (MANE)

Veradermics shares are trading higher after the company announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss.